Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, double-blind, placebo-controlled study of PRI-002 in MCI or mild Alzheimer's disease
2022-503148-41-00Phase 2Completed
- Sponsor
- PRInnovation GmbH
- Start
- Oct 2023
- Modality
- Peptides
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing PRI-002 with Placebo (2 arms). Primary endpoints: Drug-related adverse events and serious adverse events at Week 48 and Change in CDR-SB at Week 48. Started Oct 2023; status: completed.
02
Drugs
PRI-002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-503148-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503148-41-00.